share_log

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on CARISMA Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.维持对CARISMA Therapeutics的买入,将目标股价下调至9美元
Benzinga ·  04/02 08:51

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price target from $11 to $9.

HC Wainwright & Co. 分析师米切尔·卡普尔维持CARISMA Therapeutics(纳斯达克股票代码:CARM)的买入并将目标股价从11美元下调至9美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发